Valuation: Damora Therapeutics, Inc.

Market Cap 1.25B 1.12B 1.04B 946M 1.78B 121B 1.8B 12.52B 4.89B 61.47B 4.69B 4.59B 198B P/E 2026 *
-10.1x
P/E 2027 * -9.74x
Enterprise Value 788M 704M 657M 597M 1.12B 76.22B 1.13B 7.89B 3.08B 38.77B 2.96B 2.89B 125B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
91.57%
Yield 2026 *
-
Yield 2027 * -
1 day+3.53%
1 week-4.89%
Current month-4.89%
1 month-32.67%
3 months-32.53%
6 months-17.05%
Current year-12.04%
1 week 18.2
Extreme 18.195
20.76
1 month 18.2
Extreme 18.195
29.29
Current year 16.5
Extreme 16.5001
34.89
1 year 4.95
Extreme 4.95
38.33
3 years 2.01
Extreme 2.01
38.33
5 years 2.01
Extreme 2.01
92.5
10 years 2.01
Extreme 2.01
449.75
Manager TitleAgeSince
Chief Executive Officer 55 30/03/2026
Director of Finance/CFO - 01/05/2026
Chief Tech/Sci/R&D Officer 60 05/01/2026
Director TitleAgeSince
Chairman 40 23/03/2026
Director/Board Member 42 10/11/2025
Director/Board Member 41 10/11/2025
Date Insider Type Main position Quantity % Market Cap. Importance
9/25/26 A Buy

Chief Executive Officer

12,500 0.0202%
8/12/26 A Free

Director

30,350 0.0493%
7/6/26 A Sell

General Counsel

-245 0.0004%
Change 5-day change 1-year change 3-year change Capi.($)
+3.53%-4.89%+12.95%+21.36% 1.25B
+4.16%+4.16%+49.37%+94.17% 74.68B
-13.74%-13.97%+5.36%+55.03% 58.7B
-1.66%+1.14%+4.07%+32.17% 48.36B
+0.50%-2.14%+331.33%+702.20% 43.05B
-0.72%-3.99%+28.50%+29.94% 42.48B
+0.34%-0.52%+6.56%+109.35% 41.39B
-0.11%+1.96%+9.19%+52.66% 31.29B
-0.50%-3.10%-10.19%-14.35% 23.93B
-3.32%-10.86%-37.32%+316.28% 22.22B
Average -1.14%-2.45%+39.98%+139.88% 38.74B
Weighted average by Cap. -1.68%-1.58%+49.51%+145.11%

Financials

2026 *2027 *
Net sales - -
Net income -126M -112M -105M -95.06M -179M -12.15B -180M -1.26B -491M -6.18B -471M -461M -19.86B -151M -135M -126M -115M -216M -14.64B -217M -1.52B -592M -7.44B -568M -556M -23.93B
Net Debt -462M -412M -385M -349M -658M -44.65B -663M -4.62B -1.81B -22.71B -1.73B -1.7B -73B -352M -314M -293M -266M -502M -34.03B -505M -3.52B -1.38B -17.31B -1.32B -1.29B -55.64B
Projected Income Statement - Annual - Damora Therapeutics, Inc.
Logo Damora Therapeutics, Inc.
Damora Therapeutics, Inc. is a biotechnology company that focuses on hematologic disorders. It is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms (MPN), including essential thrombocythemia and myelofibrosis, where there is significant medical need for disease-modifying treatments. Its lead asset, DMR-001, is an investigational monoclonal antibody therapy targeting mutant calreticulin (mutCALR). It is developing candidates for treatment of essential thrombocythemia (ET), an MPN associated with the overproduction of platelets, and myelofibrosis, an MPN involving the overproliferation of blood cells and deposition of fibrous material in the bone marrow and spleen. DMR-002, an afucosylated antibody designed to enhance antibody-dependent cellular cytotoxicity and amplify natural immune killing of malignant cells. DMR-003, a bi-specific T-cell engager antibody designed to recruit and direct T-cell-mediated killing of malignant cells.
Employees
7
Date Price Change Volume
07/10/26 $20.24 +3.53% 488,752
06/10/26 $19.55 -3.31% 1,171,650
05/10/26 $20.22 -2.08% 556,056
02/10/26 $20.65 +2.08% 692,889
01/10/26 $20.23 -4.93% 354,653
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Ratings Surperformance© - Damora Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
20.24USD
Average target price
46.89USD
Spread / Average Target
+131.66%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Damora Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. DMRA Stock